Who GLP-1 medication is — and isn’t — for

“Prescription-only” is a safety feature, not a hurdle. Here’s how clinicians decide whether GLP-1 treatment fits you.

V

By The Vive Team

June 2026 · 6 min read

The most important thing to understand about GLP-1 medication is that it is prescription-only — and that “prescription-only” is a safety feature, not a hurdle. A clinician’s job is to confirm it is appropriate for you before anything is dispensed, and to keep checking as you go.

Where clinicians usually start

For weight management, prescribing decisions generally begin with your body-mass index alongside your health history — for example a BMI in the overweight or obese range, particularly when weight is already affecting your health. But BMI is only a starting point, not a verdict; a physician reads it in the context of the whole person.

Histories that rule it out

Some histories make GLP-1 medicines inappropriate. They are not prescribed:

  • during pregnancy, breastfeeding, or when you are planning to become pregnant;
  • for people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2);
  • for people with a history of pancreatitis or a serious allergy to GLP-1 medicines.

Other conditions — gallbladder disease, certain gut disorders, some psychiatric histories — do not automatically rule treatment out but change how, or whether, a clinician proceeds.

It’s a benefit-versus-risk judgment

Beyond contraindications, a physician weighs your overall health, current medicines and goals to decide whether the benefit outweighs the risk — and which medicine and dose fit best, if any. Two people with the same weight can get different recommendations, and that is the point of an individual review.

If it isn’t right for you

A good service tells you so. At Vive you are never charged for medication that was not prescribed, and the physician will explain why and point you toward safer options where they exist. Being told “not this, not now” is the system working — not failing.

// References

  1. 1.Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). N Engl J Med. 2015;373:11–22. View study →
  2. 2.Product prescribing information for GLP-1 receptor agonists (contraindications: personal/family history of MTC or MEN 2; pregnancy).

Provided for education only. Trial averages describe study populations, not any individual’s expected result. This is not medical advice — GLP-1 medication is prescription-only and outcomes vary.

Medically reviewed by Vive’s licensed physicians. Meet the clinicians →

Curious what’s right for you?

Take the 3-min quiz →